Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Carrie Robinson

Nurse Practitioner Hattiesburg, MS Nurse Practitioner

NPI 1538872932 CMS profile 11391136

415 S 28Th Ave, Hattiesburg, MS 39401

Open in the dashboard

General payments

$1,380

83 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carrie Robinson of Hattiesburg, MS is reported in the CMS Open Payments database as having received $1,380 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $146 7
2024 General $488 26
2023 General $746 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Robinson
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Carrie Robinson were reported at $146. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Carrie Robinson Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $746 $166 $54–$529 $160
2024 $488 $173 $55–$556 $164
2025 $146 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $420 21 payments
  2. AbbVie, Inc. $299 26 payments
  3. Lilly USA, LLC $93 5 payments
  4. Novo Nordisk Inc $88 5 payments
  5. Otsuka America Pharmaceutical, Inc. $73 4 payments
  6. AstraZeneca Pharmaceuticals LP $70 4 payments
  7. Viatris Specialty LLC $65 3 payments
  8. GlaxoSmithKline, LLC. $64 3 payments
  9. Novartis Pharmaceuticals Corporation $39 2 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $34 2 payments
  11. Other $137 8 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $1,380 83 payments
Products named General payments · program years 2023–2025
  1. XIFAXAN $420 21 payments
  2. VRAYLAR $182 17 payments
  3. QULIPTA $112 8 payments
  4. MOUNJARO $77 4 payments
  5. YUPELRI $65 3 payments
  6. SHINGRIX $64 3 payments
  7. FARXIGA $57 3 payments
  8. UBRELVY $47 4 payments
  9. TRELEGY ELLIPTA $44 2 payments
  10. AREXVY $44 2 payments
  11. Other $435 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 127 drugs

Part D claims

5,726

Median for Nurse Practitioner: 389

Drug cost

$282,597

Median for Nurse Practitioner: $21,885

Branded share of claims

16.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 50 $57,700
Farxiga Dapagliflozin Propanediol Brand 36 $31,469
Eliquis Apixaban Brand 33 $29,563
Jardiance Empagliflozin Brand 21 $22,184
Xarelto Rivaroxaban Brand 25 $19,431
Mounjaro Tirzepatide Brand 14 $15,824
Linzess Linaclotide Brand 27 $15,683
Januvia Sitagliptin Phosphate Brand 21 $15,538
Trulicity Dulaglutide Brand 14 $13,086
Tresiba Flextouch U-100 Insulin Degludec Brand 11 $6,492

The 10 drugs with the highest cost, of 127 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $159
$159 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $42
$42 36 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $39
$39 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $36
$36 — —
MOUNJARO
  • Lilly USA, LLC $32
$32 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record